EUCTR2020-003655-15-PL进行中（未招募）1 期
A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy. - CheckMate-67T:CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 67T
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 495
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria:
- •- Histological confirmation of renal cell carcinoma (RCC) with a clear cell component, including participants who may also have sarcomatoid features.
- •- Advanced RCC (not amenable to curative surgery or radiation therapy) or metastatic RCC (Stage IV).
- •- Measurable disease as defined by Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria within 28 days prior to randomization.
- •- Received no more than 2 prior systemic treatment regimens.
- •- Intolerance or progression on or after the last treatment regimen received and within 6 months prior to randomization.
- •- Karnofsky PS = 70 at screening.
- •- Must agree to follow specific methods of contraception, if applicable.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 216
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 279
排除标准
- •Exclusion Criteria:
- •- Untreated, symptomatic central nervous system (CNS) metastases.
- •- Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to randomization.
- •- Active, known, or suspected autoimmune disease.
- •- Known human immunodeficiency virus (HIV) positive with an acquired immunodeficiency syndrome (AIDS) defining opportunistic infection within the last year, or a current
- •CD4 count < 350 cells/µL.
- •Participants with HIV are eligible if:
- •1. They have received established antiretroviral therapy (ART) for at
- •least 4 weeks prior to randomization.
- •2. They continue on ART as clinically indicated while enrolled on study.
- •3. CD4 counts and viral load are monitored per standard of care by a local healthcare provider.
- •4. Inclusion of participants with HIV should be based on Investigator clinical judgment in consultation with
- •the Medical Monitor.
- •NOTE: Testing for HIV must be performed at sites where mandated locally. HIV- positive participants must be excluded where mandated locally.
- •- Serious or uncontrolled medical disorders including for example, active severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) infection within approximately 4 weeks prior to screening. In the case of prior SARS-CoV-2 infection, acute symptoms must have resolved based on
- •investigator clinical judgment and, in consultation with Medical Monitor, there are no sequelae that would place the participant at a higher risk of receiving investigational treatment to be eligible.
- •- Prior treatment with a programmed death receptor-1 (anti-PD-1), programmed death ligand-1 (anti-PD-L1), or cytotoxic T-lymphocyte associated antigen-4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co stimulation or checkpoint pathways.
- •- Treatment with any live attenuated vaccine within 30 days of first study treatment.
- •- Other protocol-defined inclusion/exclusion criteria apply.
研究者
相似试验
进行中（未招募）
1 期
A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMedDRA version: 21.1Level: LLTClassification code 10050076Term: Metastatic renal carcinomaSystem Organ Class: 100000004864EUCTR2020-003655-15-FRBristol-Myers Squibb International Corporation458
招募中
3 期
A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell Carcinoma2023-503280-42-00Bristol-Myers Squibb Services Unlimited Company134
进行中（未招募）
1 期
A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMedDRA version: 21.1Level: LLTClassification code 10050076Term: Metastatic renal carcinomaSystem Organ Class: 100000004864EUCTR2020-003655-15-PTBristol-Myers Squibb International Corporation458
进行中（未招募）
1 期
A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell CarcinomaEUCTR2020-003655-15-CZBristol-Myers Squibb International Corporation458
进行中（未招募）
1 期
A Study of Subcutaneous Nivolumab in Previously Treated Advanced or Metastatic Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMedDRA version: 21.1Level: LLTClassification code 10050076Term: Metastatic renal carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003655-15-FIBristol-Myers Squibb International Corporation495